Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Switzerland
/
Pharmaceuticals & Biotech
/
Tecan Group
TECN
Tecan Group
Tariffs And Disruptions Will Crush Margins While Cuts Will Help
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
19 Jul 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CHF 165.20
6.1% overvalued
intrinsic discount
16 Aug
CHF 175.30
Loading
1Y
-38.7%
7D
2.8%
Author's Valuation
CHF 165.2
6.1% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CHF 165.2
6.1% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
1b
2014
2017
2020
2023
2025
2026
2028
Revenue CHF 1.0b
Earnings CHF 91.5m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
7.28%
Life Sciences revenue growth rate
0.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
4.42%
Calculation
CHF 91.51m
Earnings '28
x
24.67x
PE Ratio '28
=
CHF 2.26b
Market Cap '28
CHF 2.26b
Market Cap '28
/
12.44m
No. shares '28
=
CHF 181.52
Share Price '28
CHF 181.52
Share Price '28
Discounted to 2025 @ 4.43% p.a.
=
CHF 159.38
Fair Value '25
